Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

KRUPA S PANDEY

Allopathic & Osteopathic Physicians Psychiatry & Neurology Neurology

NPI
1255501508
CMS profile
102237
Location
ALBANY, NY

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2024 · Entire year

$74,709.61

112 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2024 · entire year · sorted by reported total

By paying entity

PY2024 · entire year · sorted by reported total

Paying entityAmountRecords
Genentech USA, Inc. $22,132.83 24
Amgen Inc. $17,178.78 20
E.R. Squibb & Sons, L.L.C. $14,870.88 10
Biogen, Inc. $14,003.57 13
GENZYME CORPORATION $3,215.00 1
TG Therapeutics, Inc. $1,807.00 2
Celgene Corporation $648.16 15
EMD Serono, Inc. $284.89 10
Novartis Pharmaceuticals Corporation $162.32 10
Genentech, Inc. $150.04 1
SK Life Science, Inc. $147.01 1
Alexion Pharmaceuticals, Inc. $52.82 2
ABBVIE INC. $35.43 2
Philips North America LLC $20.88 1

Page 2 of 3; records 51–100 of 112 matching records. This page contains 50 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

KRUPA S PANDEY

NPI 1255501508 · CMS profile ID 102237

Allopathic & Osteopathic Physicians / Psychiatry & Neurology / Neurology

ALBANY, NY

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 2 of 3; records 51–100 of 112 matching records. This page contains 50 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1255501508?year=2024&recipient=provider&page=2#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
KRUPA S PANDEY, NPI 1255501508, CMS profile ID 102237. General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 3; records 51–100 of 112 matching records. This page contains 50 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1255501508?year=2024&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff.
APA 7
IndustryPayments. (2026). KRUPA S PANDEY, NPI 1255501508, CMS profile ID 102237. General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 3; records 51–100 of 112 matching records. This page contains 50 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1255501508?year=2024&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff.
Bluebook
KRUPA S PANDEY, NPI 1255501508, CMS profile ID 102237, IndustryPayments, General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 2 of 3; records 51–100 of 112 matching records. This page contains 50 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff. https://industrypayments.org/provider/npi-1255501508?year=2024&recipient=provider&page=2#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2024

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2024 · Physicians and non-physician practitioners · CMS publication 2026-06-30

112 matching records · $74,709.61 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 112 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 51–100 of 112.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Novartis Pharmaceuticals Corporation $18.5607/18/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1087158509 CMS
Genentech USA, Inc. $7.9407/17/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1133050171 CMS
Biogen, Inc. $25.1207/10/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1104822012 CMS
Biogen, Inc. $3,425.0007/09/2024 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1104808671 CMS
GENZYME CORPORATION $3,215.0007/06/2024 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1139797988 CMS
EMD Serono, Inc. $16.4207/03/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1120219177 CMS
Biogen, Inc. $26.8206/26/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1104822014 CMS
Celgene Corporation $15.9906/26/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1101124882 CMS
Celgene Corporation $0.5406/26/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1101124884 CMS
Genentech USA, Inc. $6.2706/26/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1133050150 CMS
Genentech USA, Inc. $3.2306/26/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1133050155 CMS
Amgen Inc. $550.0006/24/2024 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1117648309 CMS
EMD Serono, Inc. $25.8506/20/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1120248991 CMS
Amgen Inc. $15.2206/14/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1111668866 CMS
Biogen, Inc. $4,110.0006/11/2024 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1104859952 CMS
Celgene Corporation $17.0005/29/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1101124874 CMS
Amgen Inc. $3,300.0005/16/2024 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1117648305 CMS
E.R. Squibb & Sons, L.L.C. $2,618.0005/15/2024 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1101385584 CMS
Amgen Inc. $81.0605/13/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1117648307 CMS
Alexion Pharmaceuticals, Inc. $29.0205/08/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1093941354 CMS
E.R. Squibb & Sons, L.L.C. $124.9805/01/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1101385586 CMS
Novartis Pharmaceuticals Corporation $9.5805/01/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1087158493 CMS
Amgen Inc. $3,300.0004/25/2024 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1117648297 CMS
Amgen Inc. $550.0004/25/2024 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1117648299 CMS
Celgene Corporation $16.2604/25/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1101124870 CMS
Celgene Corporation $0.3404/25/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1101124872 CMS
Amgen Inc. $85.7604/24/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1117648295 CMS
Amgen Inc. $25.0004/24/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1117648301 CMS
Genentech USA, Inc. $3,450.0004/24/2024 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1133050134 CMS
Genentech USA, Inc. $136.3704/24/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1133050138 CMS
Amgen Inc. $147.2004/18/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1117648303 CMS
EMD Serono, Inc. $23.9404/18/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1120242141 CMS
Novartis Pharmaceuticals Corporation $18.2804/18/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1087158491 CMS
Celgene Corporation $96.9804/15/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1101124868 CMS
Biogen, Inc. $171.0004/10/2024 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1104848632 CMS
Novartis Pharmaceuticals Corporation $21.5504/03/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1087158473 CMS
Amgen Inc. $14.4003/25/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1111668858 CMS
Celgene Corporation $3.5403/22/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1101124864 CMS
Celgene Corporation $3.2203/22/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1101124866 CMS
Genentech USA, Inc. $10.8903/20/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1133050146 CMS
Novartis Pharmaceuticals Corporation $20.2403/15/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1087158475 CMS
E.R. Squibb & Sons, L.L.C. $2,618.0003/13/2024 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1101385576 CMS
Celgene Corporation $300.0003/11/2024 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1101124912 CMS
SK Life Science, Inc. $147.0103/11/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1154142849 CMS
Genentech USA, Inc. $6,210.0003/09/2024 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1133050159 CMS
Genentech USA, Inc. $127.3903/09/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1133050163 CMS
Genentech USA, Inc. $337.7003/09/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1133050167 CMS
E.R. Squibb & Sons, L.L.C. $113.9602/27/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1101385574 CMS
Novartis Pharmaceuticals Corporation $18.3502/15/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1087158481 CMS
Biogen, Inc. $2,055.0002/08/2024 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1104831124 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $61,555.20 110
PY2020 $34,440.52 63
PY2021 $49,918.92 88
PY2022 $66,000.19 140
PY2023 $70,560.50 122
PY2024 $74,709.61 112
PY2025 $76,249.20 106

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Recipient $9,000.00 2
PY2025 Principal investigator $847,140.85 74
PY2024 Recipient $1,997.07 3
PY2024 Principal investigator $606,334.58 47
PY2023 Recipient $2,028.52 1
PY2023 Principal investigator $688,278.37 34
PY2022 Principal investigator $769,472.90 52
PY2021 Principal investigator $282,933.04 21
PY2020 Principal investigator $12,386.40 3
PY2019 Recipient $660.00 2
PY2019 Principal investigator $118,796.16 3

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

76 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 Amgen Inc. $1,733.00 11/20/2025 Covered Recipient Teaching Hospital
JERSEY SHORE UNIVERSITY MED CTR
A Randomized, Double-blind, Parallel-group Study to Compare Pharmacokinetics, Pharmacodynamics, Clinical Effects, and Safety Between ABP 692 and Ocrevus (Ocrelizumab) in Subjects With Relapsing-remitting Multiple Sclerosis No dispute reported 06/30/2026 1246637492
Principal investigator 1 E.R. Squibb & Sons, L.L.C. $233,091.19 11/17/2025 Covered Recipient Teaching Hospital
Jfk University Medical Center
A Phase 1, Multicenter, Single-arm, Dose-escalation Study Of CC-97540 (BMS-986353), CD19-Targeted NEX-T Chimeric Antigen Receptor (CAR) T Cells, Evaluating Safety and Tolerability in Participants with Autoimmune Neurological Diseases: Relapsing Forms of Multiple Sclerosis (RMS), Progressive Forms of Multiple Sclerosis (PMS), or Refractory Myasthenia Gravis (MG) (Breakfree-2) No dispute reported 06/30/2026 1236000954
Principal investigator 1 Genentech, Inc. $4,164.00 10/28/2025 Covered Recipient Teaching Hospital
Hackensack University Medical Center
A PHASE III STUDY TO EVALUATE THE EFFICACY AND SAFETY OF FENEBRUTINIB IN ADULTS WITH PROGRESSIVE MS No dispute reported 06/30/2026 1211533990
Principal investigator 1 Genentech, Inc. $29,547.00 10/28/2025 Covered Recipient Teaching Hospital
Hackensack University Medical Center
A PHASE III STUDY TO EVALUATE THE EFFICACY AND SAFETY OF FENEBRUTINIB IN ADULTS WITH PROGRESSIVE MS No dispute reported 06/30/2026 1211533994
Principal investigator 1 Genentech, Inc. $68.00 10/22/2025 Covered Recipient Teaching Hospital
Hackensack University Medical Center
Assessing disease activity in minority patients with relapsing multiple sclerosis using Ocrelizumab No dispute reported 06/30/2026 1211533826
Principal investigator 1 Genentech, Inc. $536.00 10/22/2025 Covered Recipient Teaching Hospital
Hackensack University Medical Center
Assessing disease activity in minority patients with relapsing multiple sclerosis using Ocrelizumab No dispute reported 06/30/2026 1211533829
Principal investigator 1 Genentech, Inc. $536.00 10/22/2025 Covered Recipient Teaching Hospital
Hackensack University Medical Center
Assessing disease activity in minority patients with relapsing multiple sclerosis using Ocrelizumab No dispute reported 06/30/2026 1211533834
Principal investigator 1 Genentech, Inc. $3,118.00 10/22/2025 Covered Recipient Teaching Hospital
Hackensack University Medical Center
Assessing disease activity in minority patients with relapsing multiple sclerosis using Ocrelizumab No dispute reported 06/30/2026 1211533843
Principal investigator 1 Novartis Pharmaceuticals Corporation $34,942.32 10/21/2025 Non-covered Recipient Entity
HACKENSACK MERIDIAN HEALTH NEUROLOGY
AGNOS: An 18-month, Open-label, Multi-Center Study to Assess the Effect of Ofatumumab 20mg SC Monthly in Treatment Nave, Very Early Relapsing Remitting Multiple Sclerosis Patients Benchmarked Against Healthy Controls on Select Outcomes No dispute reported 06/30/2026 1190307911
Principal investigator 1 Genentech, Inc. $16,264.80 10/17/2025 Covered Recipient Teaching Hospital
Hackensack University Medical Center
Assessing disease activity in minority patients with relapsing multiple sclerosis using Ocrelizumab No dispute reported 06/30/2026 1211533838
Principal investigator 1 EMD Serono, Inc. $345.00 09/24/2025 Non-covered Recipient Entity
Advarra, Inc.
Effectiveness of Switching to Cladribine Tablets in Multiple Sclerosis Patients with High Disease Activity or Disease Breakthrough in a US Real-World Population (HDA Switch Study) No dispute reported 06/30/2026 1240118053
Principal investigator 1 Genentech, Inc. $136.00 09/24/2025 Covered Recipient Teaching Hospital
Hackensack University Medical Center
A PHASE III STUDY TO EVALUATE THE EFFICACY AND SAFETY OF FENEBRUTINIB IN ADULTS WITH PROGRESSIVE MS No dispute reported 06/30/2026 1211533966
Principal investigator 1 Genentech, Inc. $12,867.00 09/24/2025 Covered Recipient Teaching Hospital
Hackensack University Medical Center
A PHASE III STUDY TO EVALUATE THE EFFICACY AND SAFETY OF FENEBRUTINIB IN ADULTS WITH PROGRESSIVE MS No dispute reported 06/30/2026 1211533985
Principal investigator 1 Roche Products Limited $328.05 09/24/2025 Covered Recipient Teaching Hospital
Hackensack University Medical Center
Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment No dispute reported 06/30/2026 1211533877
Principal investigator 1 Roche Products Limited $328.05 09/24/2025 Covered Recipient Teaching Hospital
Hackensack University Medical Center
Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment No dispute reported 06/30/2026 1211533893
Principal investigator 1 Roche Products Limited $328.05 09/24/2025 Covered Recipient Teaching Hospital
Hackensack University Medical Center
Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment No dispute reported 06/30/2026 1211533897
Principal investigator 1 Genentech, Inc. $1,072.00 09/11/2025 Covered Recipient Teaching Hospital
Hackensack University Medical Center
Assessing disease activity in minority patients with relapsing multiple sclerosis using Ocrelizumab No dispute reported 06/30/2026 1211533815
Principal investigator 1 Genentech, Inc. $923.00 09/11/2025 Covered Recipient Teaching Hospital
Hackensack University Medical Center
Assessing disease activity in minority patients with relapsing multiple sclerosis using Ocrelizumab No dispute reported 06/30/2026 1211533818
Principal investigator 1 Genentech, Inc. $68.00 08/20/2025 Covered Recipient Teaching Hospital
Hackensack University Medical Center
Assessing disease activity in minority patients with relapsing multiple sclerosis using Ocrelizumab No dispute reported 06/30/2026 1211533807
Principal investigator 1 Genentech, Inc. $1,072.00 08/20/2025 Covered Recipient Teaching Hospital
Hackensack University Medical Center
Assessing disease activity in minority patients with relapsing multiple sclerosis using Ocrelizumab No dispute reported 06/30/2026 1211533810
Principal investigator 1 Genentech, Inc. $8,132.40 08/18/2025 Covered Recipient Teaching Hospital
Hackensack University Medical Center
Assessing disease activity in minority patients with relapsing multiple sclerosis using Ocrelizumab No dispute reported 06/30/2026 1211533821
Principal investigator 1 Roche Products Limited $1,000.00 08/01/2025 Covered Recipient Teaching Hospital
Hackensack University Medical Center
Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment No dispute reported 06/30/2026 1211533888
Principal investigator 1 Genentech, Inc. $5,942.00 07/21/2025 Covered Recipient Teaching Hospital
Hackensack University Medical Center
A PHASE III STUDY TO EVALUATE THE EFFICACY AND SAFETY OF FENEBRUTINIB IN ADULTS WITH PROGRESSIVE MS No dispute reported 06/30/2026 1211533958
Principal investigator 1 Roche Products Limited $328.05 07/10/2025 Covered Recipient Teaching Hospital
Hackensack University Medical Center
Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment No dispute reported 06/30/2026 1211533881
Principal investigator 1 Roche Products Limited $328.05 07/10/2025 Covered Recipient Teaching Hospital
Hackensack University Medical Center
Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment No dispute reported 06/30/2026 1211533885
Principal investigator 1 Roche Products Limited $328.05 07/10/2025 Covered Recipient Teaching Hospital
Hackensack University Medical Center
Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment No dispute reported 06/30/2026 1211533900
Principal investigator 1 Roche Products Limited $114.85 07/10/2025 Covered Recipient Teaching Hospital
Hackensack University Medical Center
Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment No dispute reported 06/30/2026 1211533903
Principal investigator 1 Genentech, Inc. $950.00 07/01/2025 Covered Recipient Teaching Hospital
Hackensack University Medical Center
A PHASE III STUDY TO EVALUATE THE EFFICACY AND SAFETY OF FENEBRUTINIB IN ADULTS WITH PROGRESSIVE MS No dispute reported 06/30/2026 1211533906
Principal investigator 1 Genentech, Inc. $38,005.20 06/20/2025 Covered Recipient Teaching Hospital
Hackensack University Medical Center
Assessing disease activity in minority patients with relapsing multiple sclerosis using Ocrelizumab No dispute reported 06/30/2026 1211533799
Recipient F. Hoffmann-La Roche AG $4,500.00 06/15/2025 Covered Recipient Physician Satralizumab Treatment in Patients With AQP4-IgGSeropositive Neuromyelitis Optica Spectrum Disorder After Rituximab Treatment: A Case Series No dispute reported 06/30/2026 1211537287
Principal investigator 1 Genentech, Inc. $1,072.00 06/09/2025 Covered Recipient Teaching Hospital
Hackensack University Medical Center
Assessing disease activity in minority patients with relapsing multiple sclerosis using Ocrelizumab No dispute reported 06/30/2026 1211533786
Principal investigator 1 Genentech, Inc. $1,702.50 06/02/2025 Covered Recipient Teaching Hospital
Hackensack University Medical Center
A PHASE III STUDY TO EVALUATE THE EFFICACY AND SAFETY OF FENEBRUTINIB IN ADULTS WITH PROGRESSIVE MS No dispute reported 06/30/2026 1211533913
Principal investigator 1 EMD Serono, Inc. $380.00 05/22/2025 Non-covered Recipient Entity
Advarra, Inc.
Effectiveness of Switching to Cladribine Tablets in Multiple Sclerosis Patients with High Disease Activity or Disease Breakthrough in a US Real-World Population (HDA Switch Study) No dispute reported 06/30/2026 1240118056
Principal investigator 1 EMD Serono, Inc. $1,345.00 05/22/2025 Non-covered Recipient Entity
Advarra, Inc.
Effectiveness of Switching to Cladribine Tablets in Multiple Sclerosis Patients with High Disease Activity or Disease Breakthrough in a US Real-World Population (HDA Switch Study) No dispute reported 06/30/2026 1240118060
Principal investigator 1 GENZYME CORPORATION $30.00 05/19/2025 Non-covered Recipient Entity
Boster Research Center Llc
A Phase 3, Randomized, Double-blind, Efficacy and Safety Study Comparing SAR442168 to Placebo in Participants With Primary Progressive Multiple Sclerosis (PERSEUS) No dispute reported 06/30/2026 1226124419
Principal investigator 1 Genentech, Inc. $16,700.00 05/14/2025 Covered Recipient Teaching Hospital
Hackensack University Medical Center
A PHASE III STUDY TO EVALUATE THE EFFICACY AND SAFETY OF FENEBRUTINIB IN ADULTS WITH PROGRESSIVE MS No dispute reported 06/30/2026 1211533953
Principal investigator 1 Genentech, Inc. $52,959.00 05/09/2025 Covered Recipient Teaching Hospital
Hackensack University Medical Center
A PHASE III STUDY TO EVALUATE THE EFFICACY AND SAFETY OF FENEBRUTINIB IN ADULTS WITH PROGRESSIVE MS No dispute reported 06/30/2026 1211533932
Principal investigator 1 EMD Serono, Inc. $1,250.00 05/05/2025 Covered Recipient Teaching Hospital
Hackensack University Medical Center
Effectiveness of Switching to Cladribine Tablets in Multiple Sclerosis Patients with High Disease Activity or Disease Breakthrough in a US Real-World Population (HDA Switch Study) No dispute reported 06/30/2026 1240117735
Principal investigator 1 Novartis Pharmaceuticals Corporation $19,520.44 04/30/2025 Non-covered Recipient Entity
HACKENSACK MERIDIAN HEALTH NEUROLOGY
A Randomized, Open Label, Multi-center, Active-comparator Study to Assess Efficacy, Safety & Tolerability of Ofatumumab 20mg sc Monthly Versus Continued Current Therapy in Relapsing-remitting Multiple Sclerosis After Elevation of Serum Neurofilament Light No dispute reported 06/30/2026 1190307917
Principal investigator 1 GENZYME CORPORATION $4,000.00 04/28/2025 Covered Recipient Teaching Hospital
Hackensack University Medical Center
A Phase 3, Randomized, Double-blind, Efficacy and Safety Study Comparing SAR442168 to Placebo in Participants With Primary Progressive Multiple Sclerosis (PERSEUS) No dispute reported 06/30/2026 1226143074
Principal investigator 1 Roche Products Limited $2,000.00 04/24/2025 Covered Recipient Teaching Hospital
Hackensack University Medical Center
Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment No dispute reported 06/30/2026 1211533870
Principal investigator 1 Roche Products Limited $4,000.00 04/24/2025 Covered Recipient Teaching Hospital
Hackensack University Medical Center
Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment No dispute reported 06/30/2026 1211533874
Principal investigator 1 Genentech, Inc. $1,072.00 04/23/2025 Covered Recipient Teaching Hospital
Hackensack University Medical Center
Assessing disease activity in minority patients with relapsing multiple sclerosis using Ocrelizumab No dispute reported 06/30/2026 1211533778
Principal investigator 1 Genentech, Inc. $923.00 04/23/2025 Covered Recipient Teaching Hospital
Hackensack University Medical Center
Assessing disease activity in minority patients with relapsing multiple sclerosis using Ocrelizumab No dispute reported 06/30/2026 1211533790
Principal investigator 1 Genentech, Inc. $8,132.40 04/17/2025 Covered Recipient Teaching Hospital
Hackensack University Medical Center
Assessing disease activity in minority patients with relapsing multiple sclerosis using Ocrelizumab No dispute reported 06/30/2026 1211533796
Principal investigator 1 Genentech, Inc. $877.50 04/10/2025 Covered Recipient Teaching Hospital
Hackensack University Medical Center
A PHASE III STUDY TO EVALUATE THE EFFICACY AND SAFETY OF FENEBRUTINIB IN ADULTS WITH PROGRESSIVE MS No dispute reported 06/30/2026 1211533939
Principal investigator 1 Genentech, Inc. $20,600.00 04/09/2025 Covered Recipient Teaching Hospital
Hackensack University Medical Center
Assessing disease activity in minority patients with relapsing multiple sclerosis using Ocrelizumab No dispute reported 06/30/2026 1211533804
Recipient F. Hoffmann-La Roche AG $4,500.00 03/31/2025 Covered Recipient Physician Satralizumab Treatment in Patients With AQP4-IgG–Seropositive Neuromyelitis Optica Spectrum Disorder After Rituximab Treatment: A Case Series No dispute reported 06/30/2026 1211537291
Principal investigator 1 E.R. Squibb & Sons, L.L.C. $6,423.21 03/25/2025 Non-covered Recipient Entity
Hackensack University Medical Center
A Phase 1, Multicenter, Single-arm, Dose-escalation Study Of CC-97540 (BMS-986353), CD19-Targeted NEX-T Chimeric Antigen Receptor (CAR) T Cells, Evaluating Safety and Tolerability in Participants with Autoimmune Neurological Diseases: Relapsing Forms of Multiple Sclerosis (RMS), Progressive Forms of Multiple Sclerosis (PMS), or Refractory Myasthenia Gravis (MG) (Breakfree-2) No dispute reported 06/30/2026 1235997023
Principal investigator 1 EMD Serono, Inc. $410.00 03/24/2025 Non-covered Recipient Entity
Advarra, Inc.
Effectiveness of Switching to Cladribine Tablets in Multiple Sclerosis Patients with High Disease Activity or Disease Breakthrough in a US Real-World Population (HDA Switch Study) No dispute reported 06/30/2026 1240118049
Principal investigator 1 EMD Serono, Inc. $440.00 03/24/2025 Non-covered Recipient Entity
Advarra, Inc.
Effectiveness of Switching to Cladribine Tablets in Multiple Sclerosis Patients with High Disease Activity or Disease Breakthrough in a US Real-World Population (HDA Switch Study) No dispute reported 06/30/2026 1240118064
Principal investigator 1 EMD Serono, Inc. $440.00 03/24/2025 Non-covered Recipient Entity
Advarra, Inc.
Effectiveness of Switching to Cladribine Tablets in Multiple Sclerosis Patients with High Disease Activity or Disease Breakthrough in a US Real-World Population (HDA Switch Study) No dispute reported 06/30/2026 1240118069
Principal investigator 1 EMD Serono, Inc. $410.00 03/24/2025 Non-covered Recipient Entity
Advarra, Inc.
Effectiveness of Switching to Cladribine Tablets in Multiple Sclerosis Patients with High Disease Activity or Disease Breakthrough in a US Real-World Population (HDA Switch Study) No dispute reported 06/30/2026 1240118072
Principal investigator 1 EMD Serono, Inc. $1,280.00 03/24/2025 Non-covered Recipient Entity
Advarra, Inc.
Effectiveness of Switching to Cladribine Tablets in Multiple Sclerosis Patients with High Disease Activity or Disease Breakthrough in a US Real-World Population (HDA Switch Study) No dispute reported 06/30/2026 1240118077
Principal investigator 1 GENZYME CORPORATION $18,550.00 03/24/2025 Covered Recipient Teaching Hospital
Hackensack University Medical Center
A Phase 3, Randomized, Double-blind, Efficacy and Safety Study Comparing SAR442168 to Placebo in Participants With Primary Progressive Multiple Sclerosis (PERSEUS) No dispute reported 06/30/2026 1226142940
Principal investigator 1 Celgene Corporation $76,348.19 03/19/2025 Covered Recipient Teaching Hospital
Jfk University Medical Center
A Phase 1, Multicenter, Single-arm, Dose-escalation Study Of CC-97540 (BMS-986353), CD19-Targeted NEX-T Chimeric Antigen Receptor (CAR) T Cells, Evaluating Safety and Tolerability in Participants with Autoimmune Neurological Diseases: Relapsing Forms of Multiple Sclerosis (RMS), Progressive Forms of Multiple Sclerosis (PMS), or Refractory Myasthenia Gravis (MG) (Breakfree-2) No dispute reported 06/30/2026 1222304525
Principal investigator 1 Genentech, Inc. $1,608.00 03/14/2025 Covered Recipient Teaching Hospital
Hackensack University Medical Center
Assessing disease activity in minority patients with relapsing multiple sclerosis using Ocrelizumab No dispute reported 06/30/2026 1211533765
Principal investigator 1 Genentech, Inc. $2,183.00 03/14/2025 Covered Recipient Teaching Hospital
Hackensack University Medical Center
Assessing disease activity in minority patients with relapsing multiple sclerosis using Ocrelizumab No dispute reported 06/30/2026 1211533774
Principal investigator 1 Genentech, Inc. $337.50 03/14/2025 Covered Recipient Teaching Hospital
Hackensack University Medical Center
A PHASE III STUDY TO EVALUATE THE EFFICACY AND SAFETY OF FENEBRUTINIB IN ADULTS WITH PROGRESSIVE MS No dispute reported 06/30/2026 1211533936
Principal investigator 1 Genentech, Inc. $14,205.60 03/05/2025 Covered Recipient Teaching Hospital
Hackensack University Medical Center
Assessing disease activity in minority patients with relapsing multiple sclerosis using Ocrelizumab No dispute reported 06/30/2026 1211533769
Principal investigator 1 Genentech, Inc. $21,257.00 02/14/2025 Covered Recipient Teaching Hospital
Hackensack University Medical Center
A PHASE III STUDY TO EVALUATE THE EFFICACY AND SAFETY OF FENEBRUTINIB IN ADULTS WITH PROGRESSIVE MS No dispute reported 06/30/2026 1211533920
Principal investigator 1 Genentech, Inc. $11,787.50 02/13/2025 Covered Recipient Teaching Hospital
Hackensack University Medical Center
Ocrevus Subcutaneous Study for Safety and Tolerability No dispute reported 06/30/2026 1211534097
Principal investigator 1 GENZYME CORPORATION $9,576.53 02/04/2025 Covered Recipient Teaching Hospital
Hackensack University Medical Center
A Phase 3, Randomized, Double-blind, Efficacy and Safety Study Comparing SAR442168 to Placebo in Participants With Nonrelapsing Secondary Progressive Multiple Sclerosis No dispute reported 06/30/2026 1226080194
Principal investigator 1 Novartis Pharmaceuticals Corporation $27,028.66 01/31/2025 Non-covered Recipient Entity
HACKENSACK MERIDIAN HEALTH NEUROLOGY
A Randomized, Open Label, Multi-center, Active-comparator Study to Assess Efficacy, Safety & Tolerability of Ofatumumab 20mg sc Monthly Versus Continued Current Therapy in Relapsing-remitting Multiple Sclerosis After Elevation of Serum Neurofilament Light No dispute reported 06/30/2026 1190307915
Principal investigator 1 GENZYME CORPORATION $4,222.09 01/21/2025 Covered Recipient Teaching Hospital
Hackensack University Medical Center
A Phase 3, Randomized, Double-blind Efficacy and Safety Study Comparing SAR442168 to Teriflunomide (Aubagio) in Participants With Relapsing Forms of Multiple Sclerosis No dispute reported 06/30/2026 1226143003
Principal investigator 1 GENZYME CORPORATION $8,751.38 01/21/2025 Covered Recipient Teaching Hospital
Hackensack University Medical Center
A Phase 3, Randomized, Double-blind Efficacy and Safety Study Comparing SAR442168 to Teriflunomide (Aubagio) in Participants With Relapsing Forms of Multiple Sclerosis No dispute reported 06/30/2026 1226143033
Principal investigator 1 GENZYME CORPORATION $2,389.50 01/21/2025 Covered Recipient Teaching Hospital
Hackensack University Medical Center
A Phase 3, Randomized, Double-blind Efficacy and Safety Study Comparing SAR442168 to Teriflunomide (Aubagio) in Participants With Relapsing Forms of Multiple Sclerosis No dispute reported 06/30/2026 1226143048
Principal investigator 1 GENZYME CORPORATION $4,222.09 01/21/2025 Covered Recipient Teaching Hospital
Hackensack University Medical Center
A Phase 3, Randomized, Double-blind Efficacy and Safety Study Comparing SAR442168 to Teriflunomide (Aubagio) in Participants With Relapsing Forms of Multiple Sclerosis No dispute reported 06/30/2026 1226143051
Principal investigator 1 GENZYME CORPORATION $8,751.38 01/21/2025 Covered Recipient Teaching Hospital
Hackensack University Medical Center
A Phase 3, Randomized, Double-blind Efficacy and Safety Study Comparing SAR442168 to Teriflunomide (Aubagio) in Participants With Relapsing Forms of Multiple Sclerosis No dispute reported 06/30/2026 1226143056
Principal investigator 1 Roche Products Limited $328.05 01/09/2025 Covered Recipient Teaching Hospital
Hackensack University Medical Center
Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment No dispute reported 06/30/2026 1211533847
Principal investigator 1 Roche Products Limited $328.05 01/09/2025 Covered Recipient Teaching Hospital
Hackensack University Medical Center
Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment No dispute reported 06/30/2026 1211533851
Principal investigator 1 Roche Products Limited $328.05 01/09/2025 Covered Recipient Teaching Hospital
Hackensack University Medical Center
Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment No dispute reported 06/30/2026 1211533855
Principal investigator 1 Roche Products Limited $328.05 01/09/2025 Covered Recipient Teaching Hospital
Hackensack University Medical Center
Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment No dispute reported 06/30/2026 1211533859
Principal investigator 1 Roche Products Limited $328.05 01/09/2025 Covered Recipient Teaching Hospital
Hackensack University Medical Center
Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment No dispute reported 06/30/2026 1211533863
Principal investigator 1 Roche Products Limited $328.05 01/09/2025 Covered Recipient Teaching Hospital
Hackensack University Medical Center
Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment No dispute reported 06/30/2026 1211533866
Principal investigator 1 Novartis Pharmaceuticals Corporation $91,391.02 01/07/2025 Non-covered Recipient Entity
HACKENSACK MERIDIAN HEALTH NEUROLOGY
AGNOS: An 18-month, Open-label, Multi-Center Study to Assess the Effect of Ofatumumab 20mg SC Monthly in Treatment Nave, Very Early Relapsing Remitting Multiple Sclerosis Patients Benchmarked Against Healthy Controls on Select Outcomes No dispute reported 06/30/2026 1190307913